Cambridge-Chennai Centre Partnership on Antimicrobial Resistant Tuberculosis

剑桥-钦奈抗微生物结核病中心合作伙伴关系

• 批准号: MR/N501864/1
• 负责人: Sharon Peacock
• 金额: $ 147.27万
• 依托单位: University of Cambridge
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FN501864%2F1
• 关键词: Cambridge; Chennai; Centre; Partnership; Antimicrobial

The need for a joint India-UK Centre Partnership focused on drug-resistant tuberculosis (TB) is founded on the scale of the problem both in India and globally, combined with the pressing need to develop new tools and therapeutics to combat it. There were 1,467,585 cases of TB notified in India during 2012 (the largest number of cases in any country worldwide), with a sharp rise in the number of people diagnosed with multidrug resistant (MDR) TB (from 308 to 16,588 laboratory confirmed cases between 2008 and 2012). Our partnership between the University of Cambridge and the National Institute for Research in Tuberculosis (NIRT) in Chennai, India, will bring together a multidisciplinary team to focus on novel diagnostics and therapeutics for TB. This includes the use of emerging sequence-based diagnostics to improve the accuracy of individual patient treatment for MDR and extensively drug resistant (XDR) TB; new drug targets for TB and prediction/investigation of the impact of resistance mutations based on modelling of bacterial genome data; the development of an in-depth understanding of the bacterial genes in diverse populations of Mycobacterium tuberculosis associated with so-called 'drug tolerance'; and novel approaches to treatment of TB based on immunomodulation (enhancement of autophagy and novel enhancers of T cell responsiveness). The Centre Partnership will generate a rich and lasting clinical and genomic dataset. Our objectives require detailed clinical and biological phenotyping and genotyping of patient cohorts, which can be mined to address future questions and will further enhance collaborative research to tackle the burden of drug-resistant TB. We will also innovate in training and knowledge transfer. Leveraging of novel technologies will increase relevant and collaborative research experience for UK and Indian investigators. Transfer of scientific training and technology to India enhances independent research capacity and fosters future international collaborative projects. This will be achieved through mobility and exchange of junior (training) and senior (discipline-hopping) researchers.

建立印度-英国联合中心合作伙伴关系，重点关注耐药结核病（TB），这是基于印度和全球结核病问题的规模，以及开发新工具和治疗方法的迫切需要。2012年，印度报告了1，467，585例结核病病例2008年，全球结核病发病率最高的国家，被诊断为耐多药结核病的人数急剧上升（2008年至2012年，实验室确诊病例从308例增至16，588例）。我们与剑桥大学和印度钦奈国家结核病研究所（NIRT）的合作将汇集一个多学科团队，专注于结核病的新诊断和治疗。这包括使用新出现的基于序列的诊断方法，以提高MDR和广泛耐药结核病（XDR）患者个体治疗的准确性;结核病的新药靶点，以及根据细菌基因组数据建模预测/调查耐药突变的影响;深入了解不同结核分枝杆菌群体中与so-以及基于免疫调节（增强自噬和T细胞反应性的新增强剂）的治疗TB的新方法。该中心的合作伙伴关系将产生一个丰富和持久的临床和基因组数据集。我们的目标需要对患者队列进行详细的临床和生物学表型和基因分型，这些表型和基因分型可以用来解决未来的问题，并将进一步加强合作研究，以应对耐药结核病的负担。我们还将在培训和知识转移方面进行创新。利用新技术将增加英国和印度研究人员的相关和合作研究经验。向印度转让科学培训和技术可提高独立研究能力，促进未来的国际合作项目。这将通过初级（培训）和高级（跨学科）研究人员的流动和交流来实现。

项目成果

Fragment screening against the EthR-DNA interaction by native mass spectrometry

通过天然质谱法筛选 EthR-DNA 相互作用的片段

• DOI: 10.17863/cam.9964
• 发表时间: 2017
• 作者: Chan D

Analysis of metabolic pathways in mycobacteria to aid drug-target identification

• DOI: 10.1101/535856
• 发表时间: 2019-01
• 期刊: bioRxiv
• 作者: Bridget P. Bannerman;S. Vedithi;J. Júlvez;P. Torres;V. Waman;A. Munir;Vítor Mendes;S. Malhotra;Marcin J. Skwark;S. Oliver;T. Blundell

Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry.

蛋白质晶体学和药物发现：学术界与工业之间知识交流的回忆。

• DOI: 10.1107/s2052252517009241
• 发表时间: 2017-07-01
• 期刊: IUCrJ
• 影响因子: 3.9
• 作者: Blundell TL

Analysis of mutations in pncA reveals non-overlapping patterns among various lineages of Mycobacterium tuberculosis.

对 pncA 突变的分析揭示了结核分枝杆菌不同谱系之间的非重叠模式。

• DOI: 10.17863/cam.28104
• 发表时间: 2018
• 作者: Baddam R